Citicoline

Alternative Medicine Review

Volumn 13, Issue 1, 2008, Pages 50-57

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; AMYLOID BETA PROTEIN; CITICOLINE; DECARBOXYLASE INHIBITOR; LEVODOPA; METHYLPREDNISOLONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NIMODIPINE; PLACEBO;

ACCIDENTAL INJURY; ALZHEIMER DISEASE; AMBLYOPIA; BIPOLAR DISORDER; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COCAINE DEPENDENCE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; GLAUCOMA; HEADACHE; HEMORRHAGIC STROKE; HUMAN; HUNTINGTON CHOREA; HYPOTENSION; MEMORY DISORDER; MONOTHERAPY; MULTIINFARCT DEMENTIA; NERVE MEMBRANE; NONHUMAN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SENILITY; SPINAL CORD INJURY; STOMACH PAIN; STROKE; TACHYCARDIA; TRAUMATIC BRAIN INJURY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 41749111595     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol 1995;17:1-54.
2. Agut J, Font E, Sacristan A, Ortiz JA. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline. Arzneimittelforschung 1983;33:1048-1050.
3. G-Coviella IL, Wurtman RJ. Enhancement by cytidine of membrane phospholipid synthesis. J Neurochem 1992;59:338-343.
4. D'Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol Res 1995;47:281-284.
5. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995;56:637-660.
6. Rao AM, Hatcher JF, Dempsey RJ. CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. J Neurosci Res 1999;58:697-705.
7. 14C CDP-choline. Arzneimittelforschung 1983;33:1066-1070.
8. de la Morena E. Efficacy of CDP-choline in the treatment of senile alterations in memory. Ann N Y Acad Sci 1991;640:233-236.
9. Plataras C, Tsakiris S, Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na(+), K(+)-ATPase in adult rats. Clin Biochem 2000;33:351-357.
10. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002;70:133-139.
11. Rao AM, Hatcher JF, Dempsey RJ. Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res 2001;893:268-272.
12. Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res 2003;73:308-315.
13. Nitta A, Itoh A, Hasegawa T, Nabeshima T. Beta-amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 1994;170:63-66.
14. Nitta A, Fukuta T, Hasegawa T, Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 1997;73:51-57.
15. Alvarez XA, Sampedro C, Lozano R, Cacabelos R. Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Methods Find Exp Clin Pharmacol 1999;21:535-540.
16. Lopez I, Coviella G, Agut J, Wurtman RJ. Effect of cytidine(5′) diphosphocholine (CDP-choline) on the total urinary excretion of 3-methoxy-4-hydroxyphenylglycol (MHPG) by rats and humans. J Neural Transm 1986;66:129-134.
17. Petkov VD, Stancheva SL, Tocuschieva L, Petkov VV. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen Pharmacol 1990;21:71-75.
18. Agut J, Coviella IL, Wurtman RJ. Cytidine(5′) diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine. Neuropharmacology 1984;23:1403-1406.
19. Adibhatla RM, Hatcher JF, Dempsey RJ. Cytidine-5′-disphosphocholine affects CTP-phosphocholine cytidylyltransferase and lyso-phosphatidylcholine after transient brain ischemia. J Neurosci Res 2004;76:390-396.
20. Hurtado O, Moro MA, Cardenas A, et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis 2005;18:336-345.
21. Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988;19:211-216.
22. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850-2857.
23. Clark WM, Warach SJ, Pettigrew LC, et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997;49:671-678.
24. Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30:2592-2597.
25. Clark WM, Wechsler LR, Sabounjian LA, et al. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57:1595-1602.
26. Secades JJ, Alvarez-Sabin J, Rubio F, et al. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis 2006;21:380-385.
27. Drago F, Mauceri F, Nardo L, et al. Effects of cytidine-diphosphocholine on acetylcholine-mediated behaviors in the rat. Brain Res Bull 1993;31:485-489.
28. Petkov VD, Kehayov RA, Mosharrof AH, et al. Effects of cytidine diphosphate choline on rats with memory deficits. Arzneimittelforschung 1993;43:822-828.
29. Bruhwyler J, Liegeois JF, Geczy J. Facilitatory effects of chronically administered citicoline on learning and memory processes in the dog. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:115-128.
30. Agnoli A, Bruno G, Fioravanti M, et al. Therapeutic approach to senile memory impairment: a double-blind clinical trial with CDP choline. In: Wurtman RJ, Corkin S, Growden JH, eds. Alzheimer's Disease: Proceedings of the Fifth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Boston, MA: Birkhauser; 1989:649-654.
31. Spiers PA, Myers D, Hochanadel GS, et al. Citicoline improves verbal memory in aging. Arch Neurol 1996;53:441-448.
32. Alvarez XA, Laredo M, Corzo D, et al. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol 1997;19:201-210.
33. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioral disturbances associated with chronic cerebral disorders in the elderly (Cochrane Review) In: The Cochrane Library. Oxford, England: Update Software; 2002:4.
34. Cohen RA, Browndyke JN, Moser DJ, et al. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. Cerebrovasc Dis 2003;16:199-204.
35. Caamano J, Gomez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol 1994;16:211-218.
36. Alvarez XA, Mouzo R, Pichel V, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol 1999;21:633-644.
37. Cacabelos R, Alvarez XA, Franco-Maside A, et al. Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia. Ann N Y Acad Sci 1993;695:321-323.
38. Leon-Carrion J, Dominguez-Roldan JM, Murillo-Cabezas F, et al. The role of citicoline in neuropsychological training after traumatic brain injury. NeuroRehabilitation 2000;44:33-40.
39. Calatayud Maldonado V, Calatayud Perez JB, Aso Escario J. Effects of CDP-choline on the recovery of patients with head injury. J Neurol Sci 1991;103:S15-S18.
40. Levin HS. Treatment of postconcussional symptoms with CDP-choline. J Neurol Sci 1991;103:S39-S42.
41. Cakir E, Usul H, Peksoylu B, et al. Effects of citicoline on experimental spinal cord injury. J Clin Neurosci 2005;12:923-926.
42. Yucel N, Cayli SR, Ates O, et al. Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioral and neuroanatomical recovery. Neurochem Res 2006;31:767-775.
43. Agnoli A, Ruggieri S, Denaro A, Bruno G. New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 1982;8:289-296.
44. Mievis S, Levivier M, Vassart G, et al. Citicoline is not protective in experimental models of Huntington's disease. Neurobiol Aging 2007;28:1944-1946.
45. Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psycopharmacol 2007;27:498-502.
46. Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Opthalmol 1982;100:135-146.
47. Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5′- diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999;106:1126-1134.
48. Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5′-diphosphocholine (citicoline): a study of 8 years of follow-up. Doc Ophthalmol 2005;110:91-102.
49. Rejdak R, Toczolowski J, Kurkowski J, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit 2003;9:P124-P128.
50. Grieb P, Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J Neurosci Res 2002;67:143-148.
51. Rejdak R, Toczolowski J, Solski J, et al. Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Res 2002;34:146-149.
52. Oshitari T, Fujimoto N, Adachi-Usami E. Citicoline has a protective effect on damaged retinal ganglion cells in mouse culture retina. Neuroreport 2002;13:2109-2111.
53. Campos EC, Schiavi C, Benedetti P, et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol 1995;233:307-312.
54. Porciatti V, Schiavi C, Benedetti P, et al. Cytidine-5′- diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr Eye Res 1998;17:141-148.
55. Dinsdale JR, Griffiths GK, Castello J, et al. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. Arzneimittelforschung 1983;33:1061-1065.
56. Lozano Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung 1983;33:1073-1080.
57. Grau T, Romero A, Sacristan A, Ortiz JA. CDP-choline: acute toxicity study. Arzneimittelforschung 1983;33:1033-1034.
58. Romero A, Grau T, Sacristan A, Ortiz JA. Study of subacute toxicity of CDP-choline after 30 days of oral administration to rats. Arzneimittelforschung 1983;33:1035-1038.
59. Romero A, Grau T, Sacristan A, Ortiz JA. CDP-choline: 6-month study on toxicity in dogs. Arzneimittelforschung 1983;33:1038-1042.